Literature DB >> 16500647

Cannabinoid derivatives induce cell death in pancreatic MIA PaCa-2 cells via a receptor-independent mechanism.

Stefano Fogli1, Paola Nieri, Andrea Chicca, Barbara Adinolfi, Veronica Mariotti, Paola Iacopetti, Maria Cristina Breschi, Silvia Pellegrini.   

Abstract

Cannabinoids (CBs) are implicated in the control of cell survival in different types of tumors, but little is known about the role of CB system in pancreatic cancer. Herein, we investigated the in vitro antitumor activity of CBs and the potential role of their receptors in human pancreatic cancer cells MIA PaCa-2. Characterization tools used for this study included growth inhibition/cell viability analyses, caspase 3/7 induction, DNA fragmentation, microarray analysis and combination index-isobologram method. Our results demonstrate that CBs produce a significant cytotoxic effect via a receptor-independent mechanism. The CB1 antagonist N-(piperidin-1-1yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (AM251) was the most active compound with an IC50 of 8.6 +/- 1.3 microM after 72 h. AM251 induces apoptosis, causes transcriptional changes of genes in janus kinase/signal transducers and activators of transcription signaling network and synergistically interacts with the pyrimidine analogue, 5-fluorouracil. These findings exclude the involvement of CB receptors in the regulation of MIA PaCa-2 cell growth and put AM251 forward as a candidate for the development of novel compounds worthy to be tested in this type of neoplasia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16500647     DOI: 10.1016/j.febslet.2006.02.024

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  18 in total

Review 1.  Neurobiological applications of small molecule screening.

Authors:  Andras Bauer; Brent Stockwell
Journal:  Chem Rev       Date:  2008-05-01       Impact factor: 60.622

2.  Evidence for bidirectional endocannabinoid transport across cell membranes.

Authors:  Andrea Chicca; Janine Marazzi; Simon Nicolussi; Jürg Gertsch
Journal:  J Biol Chem       Date:  2012-08-09       Impact factor: 5.157

3.  Potentiation of the antitumor activity of adriamycin against osteosarcoma by cannabinoid WIN-55,212-2.

Authors:  Feng Niu; Song Zhao; Chang-Yan Xu; Hui Sha; Gui-Bin Bi; Lin Chen; Long Ye; Ping Gong; Tian-Hong Nie
Journal:  Oncol Lett       Date:  2015-07-23       Impact factor: 2.967

Review 4.  Targeting the Endocannabinoid System: From the Need for New Therapies to the Development of a Promising Strategy. What About Pancreatic Cancer?

Authors:  Nikolaos Garmpis; Christos Damaskos; Dimitrios Dimitroulis; Anna Garmpi; Evangelos Diamantis; Panagiotis Sarantis; Vasiliki E Georgakopoulou; Alexandros Patsouras; Dionysios Prevezanos; Athanasios Syllaios; Georgios Kyriakos; Evangelos Koustas; Markos Despotidis; Christos Vallilas; Petros Papalexis; Efstathios A Antoniou; Konstantinos Kontzoglou; Gregory Kouraklis
Journal:  In Vivo       Date:  2022 Mar-Apr       Impact factor: 2.155

5.  Synthesis and antitumour evaluation of indole-2-carboxamides against paediatric brain cancer cells.

Authors:  Shahinda S R Alsayed; Amreena Suri; Anders W Bailey; Samuel Lane; Eryn L Werry; Chiang-Ching Huang; Li-Fang Yu; Michael Kassiou; Simone Treiger Sredni; Hendra Gunosewoyo
Journal:  RSC Med Chem       Date:  2021-08-23

6.  Cannabinoids as anticancer therapeutic agents.

Authors:  Olga Kovalchuk; Igor Kovalchuk
Journal:  Cell Cycle       Date:  2020-04-05       Impact factor: 4.534

7.  Cannabinoids in pancreatic cancer: correlation with survival and pain.

Authors:  Christoph W Michalski; Florian E Oti; Mert Erkan; Danguole Sauliunaite; Frank Bergmann; Pal Pacher; Sandor Batkai; Michael W Müller; Nathalia A Giese; Helmut Friess; Jörg Kleeff
Journal:  Int J Cancer       Date:  2008-02-15       Impact factor: 7.396

Review 8.  Cannabinoids as therapeutic agents in cancer: current status and future implications.

Authors:  Bandana Chakravarti; Janani Ravi; Ramesh K Ganju
Journal:  Oncotarget       Date:  2014-08-15

9.  The synthetic cannabinoid WIN55,212-2 mesylate decreases the production of inflammatory mediators in rheumatoid arthritis synovial fibroblasts by activating CB2, TRPV1, TRPA1 and yet unidentified receptor targets.

Authors:  Torsten Lowin; Georg Pongratz; Rainer H Straub
Journal:  J Inflamm (Lond)       Date:  2016-05-05       Impact factor: 4.981

10.  Cannabinoid Receptors Are Overexpressed in CLL but of Limited Potential for Therapeutic Exploitation.

Authors:  Patricia Freund; Edit A Porpaczy; Trang Le; Michaela Gruber; Clemens Pausz; Philipp Staber; Ulrich Jäger; Katrina Vanura
Journal:  PLoS One       Date:  2016-06-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.